Amarin Corp Plc (AMRN)

[north40000]

Thanks, Mikenac. In JAMA’s interview with Dr. Peterson, he confirmed our view(seen by a number of us at AHA in Chicago about 2:00 pm) that the results presented concerning the Vital clinical trial were quite poor; he thought the Vital trial demonstrated that clinicians would find low dose EPA( even when combined with Vitamin D3, in commonly available OTC or DES formats) would be of no benefit to patients under their care.

Dr. Peterson’s views regarding the Reduce-It trial of Amarin were in stark contrast to his views re Vital, opining that Vascepa dosages would be very useful for patients as part of a CVD treatment procedure.